Help4HD

Help4HD

×  

Follow This Show

If you liked this show, you should follow Help4HD.

The HD View with First HD Crew

  Broadcast in Science

Call in to speak with the host

(310) 982-4227

Tuesday, November 12, 2013

Join us for an update on the HSG First-HD clinical trial with incredible special guests Jody Goldstein from Rochester and Greg Suter from the HNDC.

 

First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months.

For more information about First-HD you can contact the HSG directly:
Toll-free number:  (800) 487-7671  (North America)
OR
email: info@hsglimited.org
Visit: www.ClinicalTrials.gov

Tags:
HSG
First HD
Clinical trials
HNDC
SD 809
h:150708
s:5680973
archived

Comments

 comments